Stephens & Co. Initiates Coverage On Actinium Pharma with Overweight Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Sudan Loganathan initiates coverage on Actinium Pharma (AMEX:ATNM) with an Overweight rating and a price target of $25.
May 14, 2024 | 9:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharma receives an Overweight rating from Stephens & Co. with a price target of $25, indicating a positive outlook on the stock.
The initiation of coverage by Stephens & Co. with an Overweight rating and a high price target of $25 suggests a strong bullish outlook for Actinium Pharma. This is likely to attract investor attention and could lead to a short-term increase in stock price due to the positive sentiment and increased visibility among investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100